AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
Portfolio Pulse from Benzinga Neuro
AstraZeneca, Merck, and GSK have struck a record $44.1 billion in licensing deals with Chinese drugmakers in 2023, driven by Western pharmaceutical companies' need to expand their product pipelines amid patent expirations. Chinese drugmakers are seeking overseas growth due to domestic funding constraints and pricing regime changes.
May 27, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca has been involved in record licensing deals with Chinese drugmakers, driven by the need to expand its product pipeline amid patent expirations.
AstraZeneca's involvement in significant licensing deals indicates a strategic move to bolster its product offerings, which is likely to positively impact its stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
GSK has participated in record licensing deals with Chinese drugmakers, aiming to expand its product pipeline amid patent expirations.
GSK's involvement in substantial licensing deals reflects its strategy to mitigate the impact of patent expirations, likely leading to a positive short-term stock impact.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Merck has signed substantial licensing deals with Chinese drugmakers, including a $70 million upfront payment for rights to a treatment for benign joint tumors.
Merck's strategic licensing deals, including a significant upfront payment, suggest a proactive approach to expanding its product pipeline, likely boosting its stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80